ArticleCancer medicine2026

Eosinophil Proportion May Serve as a Candidate Biomarker for Adverse Events in Patients With Urothelial Carcinoma Treated With Enfortumab Vedotin.

Kunihiro Odagiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.